₹1700.5
-0.08% today
· 30d +7.78%
as of 2026-09-04
Price · Daily Candles
“Venus Remedies sees explosive Q1 profit alongside FII stake increase, yet growth forecasts face FCF pressure.”
Venus Remedies posted a strong Q1 2026, with net profit surging by 139.27% YoY to ₹23 Cr and revenue increasing by 35.6% YoY to ₹179 Cr. This robust performance comes despite ML predictions indicating a weak forecast for free cash flow (FCF), with a 1-year rolling 4-year FCF rank of 0.0. The stock has seen significant price appreciation, up 253.03% over the last year, while FIIs increased their holding by 0.12% QoQ.
BULL CASE
+Q1 2026 net profit soared by 139.27% YoY to ₹23 Cr, demonstrating strong earnings momentum.
+Quarterly revenue grew by 35.6% YoY to ₹179 Cr, accompanied by a 95.8% YoY increase in operating profit.
+The company's stock has delivered exceptional returns, up 253.03% over the past year and 64.73% in the last three months.
+Annual net profit grew by 126.79% YoY to ₹103 Cr in FY26, with a 3-year net profit CAGR of 56.98%.
+FIIs marginally increased their stake by 0.12% QoQ to 2.92% in Q1 2026.
BEAR CASE
−ML models predict severe FCF compression, with the 1-year FCF rolling 4-year rank at 0.0, suggesting potential future cash flow challenges.
−Despite strong profit growth, the company's ROCE stands at 11.0%, significantly lower than sector peers like Sun Pharma (22.46%) and Cipla (25.09%).
−DIIs reduced their stake by 0.31% QoQ, currently holding 0.89% in Q1 2026.
−The stock is currently trading 17.49% below its 52-week high of ₹2044.3.
−The ML rankings for Free Cash Flow (FCF) are weak across various lookback periods, with ranks of 0.165, 0.0, and 0.037 for recent 2-year, rolling 4-year, and stable 7-year respectively.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹179 Cr
+35.6% YoY
NET PROFIT
₹23 Cr
+139.27% YoY
OPM
20.28%
+6.91pp YoY
EPS
₹17.18
PE 19.41
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-50.0%, h2=-50.0%, h3=-50.0% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
Venus Remedies, with a PE of 19.41 and ROCE of 11.0%, trails sector leaders like Cipla (PE 29.6, ROCE 25.09%) and Sun Pharma (PE 42.56, ROCE 22.46%) in profitability and valuation metrics.
PEERPEROCE %
VENUSREM19.4111.0
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
77
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
STRONG
100
Valuation
CHEAP
75
Growth
STRONG
75
Profitability
DECENT
68
Technicals
NEUTRAL
55
Risk
LOW
90
Key Stats
TTM PE
19.41
P/B
3.39
52W HIGH
₹2044.3
OFF HIGH
-16.82%
DIV YIELD
0.56%
MKT CAP
₹2276 Cr
◉ Active Signals
MACDNeutral-0.6975
RSI(14)Neutral53.64
⧉ Strategy Fit 🔒